1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor.
Saved in:
| Title: | 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor. |
|---|---|
| Authors: | Mezquita, L.1 (AUTHOR), Xenophontos, E.2 (AUTHOR), Pretzenbaher, Y.3 (AUTHOR), Sureda, C.4 (AUTHOR), Nadal, E.5 (AUTHOR), Al-Rabi, K.6 (AUTHOR), Rousseau Bussac, G.7 (AUTHOR), Ponce Aix, S.8 (AUTHOR), Sullivan, I.G.9 (AUTHOR), Calles Blanco, A.10 (AUTHOR), Cloarec, N.11 (AUTHOR), De Langen, J.12 (AUTHOR), Berghmans, T.13 (AUTHOR), Descourt, R.14 (AUTHOR), Hendriks, L.15 (AUTHOR), Garrido Lopez, P.16 (AUTHOR), Helland, A.17 (AUTHOR), Carcereny, E.18 (AUTHOR), Besse, B.19 (AUTHOR), Dingemans, A-M.C.20 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS849-S850. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
